Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

RhoA-induced suppression of the HSR decreases cell stress resistance and induces cell death via apoptosis. by Roelien A. M. Meijering (217816)

Dex increases migration independently of WNT5A/Frizzled-5 interaction. by Martin Crozier (13804275)

Sirt5 KO induces increased lysine succinylation and decreased ATP synthase activity in mouse heart mitochondria. by Mengli Zhang (6331172)

Activin A decreases MPTP and LPS-induced inflammation. by Sandy Stayte (728461)

“…<p>Stereological quantification of the left SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and Iba1-immunoreactive cells (B) in the SNpc following MPTP. …”

Grey matter concentration decreases for (A) tinnitus duration. by Sven Vanneste (202029)

“…<p>Grey matter decrease projected onto a T1-weighted image. Maximum intensity projection with a threshold of <i>p</i> < .001 (uncorrected) at both voxel and cluster level. …”

siRNA-mediated depletion of CUL5 in HUVEC prevents thalidomide-dependent decrease in cellular proliferation. by Bryan Kunkler (5204327)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Decreased expression of genes related with cell cycle and growth signaling in the lung tissue during infection with HeV and NiV-B. by Alberto J. Leon (132911)

BoNT/A (3.5 U/kg) decreases dural extravasation in IoNC-injured rats which is prevented by intraganglionic colchicine. by Boris Filipović (336089)

Dose-dependent inhibition of V-ATPase with Bafilomycin A1 decreases LysoTracker Red fluorescence and increases Lyso-pHluorin fluorescence. by Yarden Golan (5924594)

BoNT/A (3.5 U/kg) decreases IoNC-induced mechanical allodynia which is prevented by intraganglionic colchicine pretreatment. by Boris Filipović (336089)

Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

“…The ACM rates were 22.5% at 30 days and rose to 26.0% at 90 days. Multivariable Cox regression showed that, after full adjustment for potential confounders, every 2-unit decrease in PNI was associated with a 10% higher 30-day mortality hazard (HR = 1.10, 95% CI = 1.05–1.15, p < 0.001) and a 9% higher 90-day mortality hazard (HR = 1.09, 95% CI = 1.04–1.14, p < 0.001). …”

Kcnk5b requires CaMKK for growth and SHH/<i>shha</i> expression. by Xiaowen Jiang (8291814)

Treatment with wt- or S360A-(A)PC decreases infarct area. by Karin C. A. A. Wildhagen (599651)

Decrease of bnAb activity during cell-cell transmission is variable and strain-dependent. by Lucia Reh (546554)